Aspire Universal Unveils $300M Precision Medicine Fund

Law360 (April 24, 2018, 3:54 PM EDT) -- Lancaster, Pennsylvania-based private equity and venture capital firm Aspire Universal on Tuesday said it had launched a $300 million fund aimed at speeding up investment, testing and approval for startups and existing ventures focused on precision medicine.

According to the firm’s announcement, the Aspire Ventures Precision Medicine Fund, which has already begun investing, concentrates on medical therapies and devices that use artificial intelligence and the Internet of Things to provide cost-effective solutions that account for individuals’ personal, genetic and biological differences.

Aspire and a member of the University of Pennsylvania Health System, Penn Medicine Lancaster General Health, have come together as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS